Showing results (341-350 of 377) with videos related to

Sort By:
Pageof 38
Journal of Gastroenterology|September 27, 2017
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosisKazuaki Chayama, Fumitaka Suzuki, Yoshiyasu Karino, et al.
In Vivo (Athens, Greece)|April 27, 2023
Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in JapanNobuyuki Yorioka, Tadashi Namisaki, Akihiko Shibamoto, et al.
Oncology Letters|September 21, 2017
Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolizationAkitoshi Douhara, Tadashi Namisaki, Kei Moriya, et al.
JGH Open : an Open Access Journal of Gastroenterology and Hepatology|June 10, 2020
Thyroid-stimulating hormone is an independent risk factor of non-alcoholic fatty liver diseaseKazuki Tahara, Takemi Akahane, Tadashi Namisaki, et al.
Diagnostics (Basel, Switzerland)|July 14, 2023
Hemoglobin and Endotoxin Levels Predict Sarcopenia Occurrence in Patients with Alcoholic CirrhosisAkihiko Shibamoto, Tadashi Namisaki, Junya Suzuki, et al.
International Journal of Hematology|February 16, 2022
The balance of comprehensive coagulation and fibrinolytic potential is disrupted in patients with moderate to severe COVID-19Tomoko Onishi, Naruto Shimonishi, Masahiro Takeyama, et al.
International Journal of Molecular Sciences|March 13, 2024
ADAMTS-13: A Prognostic Biomarker for Portal Vein Thrombosis in Japanese Patients with Liver CirrhosisJunya Suzuki, Tadashi Namisaki, Hiroaki Takya, et al.
Hepatology Communications|February 7, 2018
Effect of combined farnesoid X receptor agonist and angiotensin II type 1 receptor blocker on hepatic fibrosisTadashi Namisaki, Kei Moriya, Mitsuteru Kitade, et al.
Medicine|September 13, 2021
The association between sarcopenia and endotoxin in patients with alcoholic cirrhosisShinya Sato, Tadashi Namisaki, Koji Murata, et al.
Experimental and Therapeutic Medicine|September 14, 2018
Efficacy and tolerability of interferon-free regimen for patients with genotype-1 HCV infectionKosuke Takeda, Ryuichi Noguchi, Tadashi Namisaki, et al.
Pageof 38